These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 23624798)

  • 1. NX-DCP as a novel biomarker would be related to liver function in cirrhotic patients with hepatocellular carcinoma.
    Hirano H; Saito M; Seo Y; Yano Y; Azuma T
    Eur J Gastroenterol Hepatol; 2013 Jun; 25(6):748-9. PubMed ID: 23624798
    [No Abstract]   [Full Text] [Related]  

  • 2. Clinical characteristics among patients with hepatocellular carcinoma according to the serum levels of alpha-fetoprotein and des-y-carboxy prothrombin.
    Dohmen K; Shigematsu H; Irie K; Ishibashi H
    Hepatogastroenterology; 2003; 50(54):2072-8. PubMed ID: 14696467
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A combination of α-fetoprotein and des-γ-carboxy prothrombin is superior in detection of hepatocellular carcinoma.
    Ertle JM; Heider D; Wichert M; Keller B; Kueper R; Hilgard P; Gerken G; Schlaak JF
    Digestion; 2013; 87(2):121-31. PubMed ID: 23406785
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sequential fluctuation pattern of serum des-gamma-carboxy prothrombin levels detected by high-sensitive electrochemiluminescence system as an early predictive marker for hepatocellular carcinoma in patients with cirrhosis.
    Shimizu A; Shiraki K; Ito T; Sugimoto K; Sakai T; Ohmori S; Murata K; Takase K; Tameda Y; Nakano T
    Int J Mol Med; 2002 Mar; 9(3):245-50. PubMed ID: 11836630
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumour-specific induction of immune complexes: DCP-IgM in hepatocellular carcinoma.
    Beneduce L; Pesce G; Gallotta A; Zampieri F; Biasiolo A; Tono N; Boscato N; Gatta A; Pontisso P; Fassina G
    Eur J Clin Invest; 2008 Aug; 38(8):571-7. PubMed ID: 18625005
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Distribution of the heterogeneity of des-gamma-carboxyprothrombin in patients with hepatocellular carcinoma.
    Uehara S; Gotoh K; Handa H; Tomita H; Senshuu M
    J Gastroenterol Hepatol; 2005 Oct; 20(10):1545-52. PubMed ID: 16174072
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Des-gamma-carboxyprothrombin, alpha-fetoprotein and AFP-L3 in patients with chronic hepatitis, cirrhosis and hepatocellular carcinoma.
    Durazo FA; Blatt LM; Corey WG; Lin JH; Han S; Saab S; Busuttil RW; Tong MJ
    J Gastroenterol Hepatol; 2008 Oct; 23(10):1541-8. PubMed ID: 18422961
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Des-gamma carboxyprothrombin can differentiate hepatocellular carcinoma from nonmalignant chronic liver disease in american patients.
    Marrero JA; Su GL; Wei W; Emick D; Conjeevaram HS; Fontana RJ; Lok AS
    Hepatology; 2003 May; 37(5):1114-21. PubMed ID: 12717392
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Des-gamma-carboxyprothrombin in patients with hepatocellular carcinoma and liver cirrhosis.
    Inagaki Y; Xu HL; Hasegawa K; Aoki T; Beck Y; Sugawara Y; Tang W; Kokudo N
    J Dig Dis; 2011 Dec; 12(6):481-8. PubMed ID: 22118699
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sensitivity and specificity of des-gamma-carboxy prothrombin for diagnosis of patients with hepatocellular carcinomas varies according to tumor size.
    Nakamura S; Nouso K; Sakaguchi K; Ito YM; Ohashi Y; Kobayashi Y; Toshikuni N; Tanaka H; Miyake Y; Matsumoto E; Shiratori Y
    Am J Gastroenterol; 2006 Sep; 101(9):2038-43. PubMed ID: 16848811
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Evaluation of diagnostic performance of alpha-fetoprotein (AFP) and des-gamma-carboxy prothrombin (DCP) for HCV related hepatocellular carcinoma developed after long-term follow up].
    Ishida H; Matsuo S; Inoue Y
    Rinsho Byori; 2010 Nov; 58(11):1065-72. PubMed ID: 21229703
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Significance of alpha-fetoprotein and des-gamma-carboxy prothrombin in patients with hepatocellular carcinoma undergoing hepatectomy.
    Yamamoto K; Imamura H; Matsuyama Y; Hasegawa K; Beck Y; Sugawara Y; Makuuchi M; Kokudo N
    Ann Surg Oncol; 2009 Oct; 16(10):2795-804. PubMed ID: 19669841
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A study about mechanisms of des-gamma-carboxy prothrombin's production in hepatocellular carcinoma.
    Bertino G; Ardiri AM; Boemi PM; Ierna D; Interlandi D; Caruso L; Minona E; Trovato MA; Vicari S; Li Destri G; Puleo S
    Panminerva Med; 2008 Sep; 50(3):221-6. PubMed ID: 18927526
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Des-gamma-carboxy prothrombin identified by P-11 and P-16 antibodies reflects prognosis for patients with hepatocellular carcinoma.
    Takeji S; Hirooka M; Koizumi Y; Tokumoto Y; Abe M; Ikeda Y; Nadano S; Hiasa Y; Onji M
    J Gastroenterol Hepatol; 2013 Apr; 28(4):671-7. PubMed ID: 23215762
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Measurement of serum levels of des-gamma-carboxy prothrombin in patients with hepatocellular carcinoma by a revised enzyme immunoassay kit with increased sensitivity.
    Okuda H; Nakanishi T; Takatsu K; Saito A; Hayashi N; Watanabe K; Magario N; Yokoo T; Naraki T
    Cancer; 1999 Feb; 85(4):812-8. PubMed ID: 10091758
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preoperative estimation of surgical risk of hepatectomy in cirrhotic patients.
    Noguchi T; Imai T; Mizumoto R
    Hepatogastroenterology; 1990 Apr; 37(2):165-71. PubMed ID: 2160419
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Des-gamma-carboxy prothrombin (DCP) ratio is a useful prognostic tumor marker for single nodule hepatocellular carcinoma (HCC).
    Murakami N; Tamano M; Yoneda M; Sugaya H; Hiraishi H
    Hepatogastroenterology; 2008; 55(81):197-201. PubMed ID: 18507106
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Utility of Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein and des-gamma-carboxy prothrombin, alone or in combination, as biomarkers for hepatocellular carcinoma.
    Sterling RK; Jeffers L; Gordon F; Venook AP; Reddy KR; Satomura S; Kanke F; Schwartz ME; Sherman M
    Clin Gastroenterol Hepatol; 2009 Jan; 7(1):104-13. PubMed ID: 18849011
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum des-gamma-carboxyprothrombin level by a modified enzyme immunoassay method in hepatocellular carcinoma: clinical significance in small hepatocellular carcinoma.
    Soga K; Watanabe T; Aikawa K; Toshima M; Shibasaki K; Aoyagi Y
    Hepatogastroenterology; 1998; 45(23):1737-41. PubMed ID: 9840138
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High serum des-gamma-carboxy prothrombin level predicts poor prognosis after radiofrequency ablation of hepatocellular carcinoma.
    Kobayashi M; Ikeda K; Kawamura Y; Yatsuji H; Hosaka T; Sezaki H; Akuta N; Suzuki F; Suzuki Y; Saitoh S; Arase Y; Kumada H
    Cancer; 2009 Feb; 115(3):571-80. PubMed ID: 19117347
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.